<DOC>
	<DOCNO>NCT02715024</DOCNO>
	<brief_summary>The objective study evaluate clinical efficacy safety tamsulosin alone combination solifenacin treatment men low urinary tract symptom ( LUTS ) include overactive bladder ( OAB ) symptoms Taiwan .</brief_summary>
	<brief_title>Study Evaluate Clinical Efficacy Safety Tamsulosin Alone Combination With Solifenacin Treatment Men With Lower Urinary Tract Symptoms Including Overactive Bladder Symptoms</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Lower Urinary Tract Symptoms</mesh_term>
	<mesh_term>Tamsulosin</mesh_term>
	<mesh_term>Solifenacin Succinate</mesh_term>
	<criteria>Clinical sign symptom frequency urgency relate benign prostatic hyperplasia least 3 month IPSS ( S ) score ≥ 12 Maximum flow rate ( Qmax ) 4 to15 mL/sec Mean urinary frequency ≥ 8 micturition per 24 hour ≥ 1 episode urgency per 24 hour verify 3day micturition diary Benign digital rectal examination ( DRE ) result Clinically significant outflow obstruction Significant post void residue volume ( PVR &gt; 100ml ) Prostate specific antigen ( PSA ) ≥10 ng/mL Previous plan prostate surgery , include transurethral resection prostate ( TURP ) Transurethral microwave treatment ( TUMT ) , transurethral needle ablation ( TUNA ) , laser , invasive minimally invasive procedure within 12 month Patient neurological cause abnormal detrusor activity Patients urinary tract infection , chronic inflammation , bladder stone , bladder neck , sclerosis , urethral stricture , prostatic cancer , severe vesical diverticulum Uncontrolled narrow angle glaucoma , urinary gastric retention medical condition opinion investigator make use anticholinergic contraindicate Patients complication may cause void dysfunction Patients severe hepatic dysfunction , severe renal dysfunction , severe cardiovascular disorder , orthostatic hypotension , senile dementia Patients receive medication therapy LUTS/BPH 2 week prior study Use drug treat incontinence currently Hypersensitivity tamsulosin and/or solifenacin component formulation Any clinically significant condition , opinion investigator make patient unsuitable trial Patients take investigational drug previous 3 month prior study</criteria>
	<gender>Male</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Tamsulosin</keyword>
	<keyword>Solifenacin</keyword>
	<keyword>Lower urinary tract symptom</keyword>
	<keyword>Overactive bladder</keyword>
</DOC>